GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avivagen Inc (TSXV:VIV) » Definitions » Return-on-Tangible-Equity

Avivagen (TSXV:VIV) Return-on-Tangible-Equity : 0.00% (As of Jul. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Avivagen Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Avivagen's annualized net income for the quarter that ended in Jul. 2023 was C$-3.73 Mil. Avivagen's average shareholder tangible equity for the quarter that ended in Jul. 2023 was C$-8.79 Mil. Therefore, Avivagen's annualized Return-on-Tangible-Equity for the quarter that ended in Jul. 2023 was N/A%.

The historical rank and industry rank for Avivagen's Return-on-Tangible-Equity or its related term are showing as below:

TSXV:VIV's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.475
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Avivagen Return-on-Tangible-Equity Historical Data

The historical data trend for Avivagen's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avivagen Return-on-Tangible-Equity Chart

Avivagen Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,676.05 - - - -

Avivagen Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Avivagen's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Avivagen's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avivagen's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avivagen's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Avivagen's Return-on-Tangible-Equity falls into.



Avivagen Return-on-Tangible-Equity Calculation

Avivagen's annualized Return-on-Tangible-Equity for the fiscal year that ended in Oct. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Oct. 2022 )  (A: Oct. 2021 )(A: Oct. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Oct. 2022 )  (A: Oct. 2021 )(A: Oct. 2022 )
=-6.066/( (-3.953+-5.984 )/ 2 )
=-6.066/-4.9685
=N/A %

Avivagen's annualized Return-on-Tangible-Equity for the quarter that ended in Jul. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jul. 2023 )  (Q: Apr. 2023 )(Q: Jul. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jul. 2023 )  (Q: Apr. 2023 )(Q: Jul. 2023 )
=-3.732/( (-8.309+-9.265)/ 2 )
=-3.732/-8.787
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jul. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Avivagen  (TSXV:VIV) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Avivagen Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Avivagen's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Avivagen (TSXV:VIV) Business Description

Traded in Other Exchanges
Address
100 Sussex Drive, Ottawa, ON, CAN, K1A 0R6
Avivagen Inc is a Canadian-based company operating in the healthcare sector. It develops science-based, natural health products for animals. It develops and commercializes products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal's health defenses. The company's products are based on OxC-beta Technology. Its geographical segments include the Philippines, which is the key revenue driver; Mexico; Thailand; United States; Malaysia; Taiwan; Brazil; and others.

Avivagen (TSXV:VIV) Headlines

From GuruFocus

1Q22 Results: Telef�nica Brasil S.A.

By PRNewswire PRNewswire 07-09-2022

1Q22 Results: Telef�nica Brasil S.A.

By PRNewswire PRNewswire 06-29-2022

1Q20 Results: Telefônica Brasil S.A.

By PRNewswire PRNewswire 05-06-2020

1Q23 Results: Telef�nica Brasil S.A.

By PRNewswire PRNewswire 05-09-2023

2Q20 Results: Telefônica Brasil S.A.

By PRNewswire PRNewswire 07-29-2020

DORCHESTER WEALTH MANAGEMENT Co Buys 2, Sells 3 in 2nd Quarter

By GuruFocus Research GuruFocus Editor 08-04-2022

Telefonica Brasil SA Stock Appears To Be Fairly Valued

By GF Value GF Value 05-03-2021